Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

, NVS

Novartis

$83.78

-0.29 (-0.34%)

08:23
08/29/18
08/29
08:23
08/29/18
08:23

Piper sees CyPass withdrawal as 'major boon' for Glaukos, ups target to $55

Piper Jaffray analyst Matt O'Brien views Alcon's immediate withdrawal of its CyPass stent for the treatment of glaucoma on safety concerns from a recently completed clinical study as a "major boon" for Glaukos (GKOS). The analyst suspects it will be several quarters before CyPass comes back to the market, with with a much narrower indication. This is a "major positive" for Glaukos as most of the clinicians using CyPass had been or are still using iStent from Glaukos, O'Brien tells investors in a research note. He anticipates many clinicians will quickly shift their volumes back to iSten, yielding "significant incremental revenues." Based on this morning's news, the analyst raised his price target for Glaukos shares to $55 from $46. He encourages investors to start or build positions in the name.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

NVS

Novartis

$83.78

-0.29 (-0.34%)

  • 05

    Sep

  • 12

    Sep

GKOS Glaukos
$44.79

-0.64 (-1.41%)

08/03/18
PIPR
08/03/18
NO CHANGE
Target $46
PIPR
Overweight
Glaukos price target raised to $46 from $38 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Glaukos to $46 citing the company's better than expected Q2 result. . The big news from the quarter is that Glaukos is pushing out the timing of iStent stand-alone by a couple years but accelerating the iDose by a year, O'Brien tells investors in a research note. He views the disclosure as a net neutral but expects the stock to trade down today. The analyst, however, believes the the pros outweigh the negatives and keeps a Overweight rating on Glaukos.
08/13/18
PIPR
08/13/18
NO CHANGE
Target $46
PIPR
Overweight
Glaukos competitor received FDA approval on Friday, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien points out that privately-held Ivantis received FDA approval on Friday for its Hydrus stent to treat glaucoma. This should be a direct competitor to Glaukos' iStent, O'Brien tells investors in a research note. Though the timing of summer 2018 was expected, shares of Glaukos are likely to pull back today on the news, the analyst contends. O'Brien, however, does not expect too much of an impact on Glaukos sales from Ivantis given that the company still has to build out a commercial sales force and ensure proper training. In addition, the analyst believes "there is plenty of room for multiple players in this market." He remains constructive on Glaukos with an Overweight rating and $46 price target.
08/24/18
WELS
08/24/18
NO CHANGE
Target $50
WELS
Outperform
Ivantis counterclaim against Glaukos looks weak, says Wells Fargo
Following a review by his firm's patent consultant, Wells Fargo analyst Larry Biegelsen says Ivantis' counterclaim, alleging that Glaukos' new iStent inject product will infringe three Ivantis patents, appears weak. The Ivantis patents very specifically add a detail about the placement of the shunt, which reads as "too straightforward" or "obvious," the patent consultant told the analyst. As such, he believes the patents will ultimately be found invalid. Biegelsen keeps an Outperform rating on Glaukos with a $50 price target.
08/29/18
WBLR
08/29/18
NO CHANGE
WBLR
Outperform
CyPass market removal a 'clear positive' for Glaukos, says William Blair
William Blair analyst Brian Weinstein believes Alcon's voluntary global market withdrawal of its CyPass Micro-Stent for surgical glaucoma is a "clear positive for near-term numbers" at Glaukos (GKOS). If Glaukos' iStent takes all of the CyPass market share while it is off the market, the company could add as much as $50M in the U.S. alone to its 2019 total revenue of around $186M, Weinstein tells investors in a research note, while admitting this is a bullish stance. The analyst thinks the news this morning from Alcon should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon. He keeps an Outperform rating on Glaukos shares.
NVS Novartis
$83.78

-0.29 (-0.34%)

08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/23/18
MSCO
08/23/18
NO CHANGE
Target $45
MSCO
Overweight
Pfizer price target raised to $45 from $43 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Pfizer (PFE) and raised his price target to $45 based upon a 5-year CAGR for revenue growth of 3% and EPS growth of 7%. In a research note to investors, Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Additionally, he notes that political news has been "encouraging" as of late, with President Trump tweeting on July 19 "Thank you to Novartis (NVS) for not increasing your prices on prescription drugs. Likewise to Pfizer." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.

TODAY'S FREE FLY STORIES

HESM

Hess Midstream Partners

$22.80

0.04 (0.18%)

16:55
04/23/19
04/23
16:55
04/23/19
16:55
Hot Stocks
Hess Midstream Partners increases quarterly dividend 3.6% to 38.3c »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

SBBX

SB One Bancorp

$22.33

0.13 (0.59%)

16:53
04/23/19
04/23
16:53
04/23/19
16:53
Earnings
SB One Bancorp reports Q1 EPS 62c, consensus 52c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

SNAP

Snap

$11.99

0.46 (3.99%)

16:52
04/23/19
04/23
16:52
04/23/19
16:52
Hot Stocks
Snap CEO: New Android OS promising, will 'take time to impact metrics' »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

DAL

Delta Air Lines

$58.23

0.49 (0.85%)

16:52
04/23/19
04/23
16:52
04/23/19
16:52
Hot Stocks
Delta Air Lines CEO sells 30,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

SLB

Schlumberger

$45.88

0.04 (0.09%)

16:50
04/23/19
04/23
16:50
04/23/19
16:50
Hot Stocks
Schlumberger CFO Simon Ayat sells 0ver $1.1M in company shares »

Schlumberger CFO Simon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 22

    May

  • 13

    Nov

CBS

CBS

$51.35

0.23 (0.45%)

16:49
04/23/19
04/23
16:49
04/23/19
16:49
Hot Stocks
CBS suspends search for new CEO, extends Ianniello as acting CEO »

Joseph Ianniello has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

MVIS

MicroVision

$0.93

-0.02 (-2.11%)

16:49
04/23/19
04/23
16:49
04/23/19
16:49
Syndicate
MicroVision raises $2M in registered direct offering »

MicroVision announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 30

    May

CBS

CBS

$51.35

0.23 (0.45%)

16:47
04/23/19
04/23
16:47
04/23/19
16:47
Periodicals
CBS suspends search for new CEO, Bloomberg says »

CBS said that Joseph…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

FE

FirstEnergy

$40.73

0.14 (0.34%)

16:44
04/23/19
04/23
16:44
04/23/19
16:44
Hot Stocks
Jersey Central Power & Light reaches pact for JCP&L Reliability Plus program »

Jersey Central Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 21

    May

NTRA

Natera

$18.99

0.84 (4.63%)

16:42
04/23/19
04/23
16:42
04/23/19
16:42
Hot Stocks
Integrated Core Strategies reports 5.3% passive stake in Natera »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 28

    May

CRI

Carter's

$105.13

2.02 (1.96%)

16:42
04/23/19
04/23
16:42
04/23/19
16:42
Initiation
Carter's initiated  »

Carter's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 16

    May

PLCE

Children's Place

$109.92

2.95 (2.76%)

16:41
04/23/19
04/23
16:41
04/23/19
16:41
Initiation
Children's Place initiated  »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAC

TransAlta

$6.88

-0.175 (-2.48%)

16:40
04/23/19
04/23
16:40
04/23/19
16:40
Hot Stocks
Mangrove Partners commences action in Ontario court against TransAlta »

Mangrove Partners, one of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

CP

Canadian Pacific

$219.33

0.215 (0.10%)

16:39
04/23/19
04/23
16:39
04/23/19
16:39
Hot Stocks
Breaking Hot Stocks news story on Canadian Pacific »

Canadian Pacific drops 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 05

    Jun

  • 13

    Nov

LLY

Eli Lilly

$117.51

2.07 (1.79%)

16:39
04/23/19
04/23
16:39
04/23/19
16:39
Upgrade
Eli Lilly rating change  »

Eli Lilly upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 04

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

16:38
04/23/19
04/23
16:38
04/23/19
16:38
General news
API crude inventories for week of April 19 »

API reports that crude…

MTH

Meritage Homes

$49.75

1.275 (2.63%)

16:38
04/23/19
04/23
16:38
04/23/19
16:38
Earnings
Meritage Homes sees FY19 EPS $4.65-$4.95, consensus $4.69 »

CEO Steven Hilton said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 17

    May

HZN

Horizon Global

$2.77

0.04 (1.47%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Hot Stocks
Horizon Global board approves amendment to declassify board structure »

Horizon Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURL

Burlington Stores

$161.96

1.76 (1.10%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Earnings
Burlington Stores narrows Q1 EPS view to $1.21-$1.25 from $1.21-$1.31 »

Q1 consensus $1.29.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

TRMK

Trustmark

$34.47

0.7 (2.07%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Earnings
Trustmark reports Q1 EPS 51c, consensus 52c »

Reports Q1 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

PRK

Park National

$95.63

2.2 (2.35%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Hot Stocks
Park National elects CEO Trautman as chairman and EVP Miller as president »

The board of directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

MTH

Meritage Homes

$49.75

1.275 (2.63%)

16:35
04/23/19
04/23
16:35
04/23/19
16:35
Earnings
Meritage Homes reports Q1 EPS 65c, consensus 64c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 17

    May

LRN

K12

$36.23

0.805 (2.27%)

16:35
04/23/19
04/23
16:35
04/23/19
16:35
Earnings
K12 sees FY19 revenue $1.005B-$1.01B, consensus $1.01B »

Sees FY19 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

LRN

K12

$36.23

0.805 (2.27%)

16:34
04/23/19
04/23
16:34
04/23/19
16:34
Earnings
K12 reports Q3 EPS 44c, consensus 37c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

ROST

Ross Stores

$97.85

0.06 (0.06%)

, BURL

Burlington Stores

$161.96

1.76 (1.10%)

16:34
04/23/19
04/23
16:34
04/23/19
16:34
Hot Stocks
Burlington Stores CEO Thomas Kingsbury to step down, Michael O'Sullivan succeeds »

Burlington Stores (BURL)…

ROST

Ross Stores

$97.85

0.06 (0.06%)

BURL

Burlington Stores

$161.96

1.76 (1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.